Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Contraception|April 1, 1983
Contraceptive efficacy of testosterone-estradiol implants in male rhesus monkeysT J Lobl, K T Kirton, A D Forbes, et al.Cardiovascular and Interventional Radiology|July 15, 2018
A Prospective Clinical Study of a Percutaneous Vascular Access System for Hemodialysis CathetersDheeraj K Rajan, Buzz Moran, Thomas J Lobl, et al.The Journal of Biological Chemistry|July 15, 1994
Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion moleculeP M Cardarelli, R R Cobb, D M Nowlin, et al.International Journal of Cancer|March 15, 1989
Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agentsD R Welch, T J Lobl, E A Seftor, et al.Cancer Research|April 18, 2001
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studiesA Trouet, A Passioukov, K Van derpoorten, et al.FEBS Letters|August 4, 1998
Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesisS A Steitz, K Hasegawa, S L Chiang, et al.Journal of Medicinal Chemistry|October 19, 2001
N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicityA M Fernandez, K Van Derpoorten, L Dasnois, et al.Antimicrobial Agents and Chemotherapy|April 18, 2002
NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against beta-lactamase-producing strainsQing Li, Jean Y Lee, Rosario Castillo, et al.Cancer Research|April 17, 2002
CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivityVincent Dubois, Luc Dasnois, Karim Lebtahi, et al.Pageof 3